114 related articles for article (PubMed ID: 26195224)
1. Variation in the inhibitory potency of terbinafine among genetic variants of CYP2D6.
Akiyoshi T; Ishiuchi M; Imaoka A; Ohtani H
Drug Metab Pharmacokinet; 2015 Aug; 30(4):321-4. PubMed ID: 26195224
[TBL] [Abstract][Full Text] [Related]
2. Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine.
Abdel-Rahman SM; Marcucci K; Boge T; Gotschall RR; Kearns GL; Leeder JS
Drug Metab Dispos; 1999 Jul; 27(7):770-5. PubMed ID: 10383919
[TBL] [Abstract][Full Text] [Related]
3. Guanfu base A, an antiarrhythmic alkaloid of Aconitum coreanum, Is a CYP2D6 inhibitor of human, monkey, and dog isoforms.
Sun J; Peng Y; Wu H; Zhang X; Zhong Y; Xiao Y; Zhang F; Qi H; Shang L; Zhu J; Sun Y; Liu K; Liu J; A J; Ho RJ; Wang G
Drug Metab Dispos; 2015 May; 43(5):713-24. PubMed ID: 25681130
[TBL] [Abstract][Full Text] [Related]
4. Genotype-sensitive reversible and time-dependent CYP2D6 inhibition in human liver microsomes.
Storelli F; Desmeules J; Daali Y
Basic Clin Pharmacol Toxicol; 2019 Feb; 124(2):170-180. PubMed ID: 30192434
[TBL] [Abstract][Full Text] [Related]
5. Functional and structural characterisation of common cytochrome P450 2D6 allelic variants-roles of Pro34 and Thr107 in catalysis and inhibition.
Dong AN; Ahemad N; Pan Y; Palanisamy UD; Yiap BC; Ong CE
Naunyn Schmiedebergs Arch Pharmacol; 2019 Aug; 392(8):1015-1029. PubMed ID: 31025144
[TBL] [Abstract][Full Text] [Related]
6. Profile of the inhibitory effects of gefitinib on CYP2D6 variants in vitro.
Semba Y; Akiyoshi T; Hibino H; Imaoka A; Ohtani H
Int J Clin Pharmacol Ther; 2020 Oct; 58(10):539-542. PubMed ID: 32691726
[TBL] [Abstract][Full Text] [Related]
7. Selective inhibition of the cytochrome P450 isoform by hyperoside and its potent inhibition of CYP2D6.
Song M; Hong M; Lee MY; Jee JG; Lee YM; Bae JS; Jeong TC; Lee S
Food Chem Toxicol; 2013 Sep; 59():549-53. PubMed ID: 23835282
[TBL] [Abstract][Full Text] [Related]
8. Kinetic mechanism of time-dependent inhibition of CYP2D6 by 3,4-methylenedioxymethamphetamine (MDMA): Functional heterogeneity of the enzyme and the reversibility of its inactivation.
Rodgers JT; Davydova NY; Paragas EM; Jones JP; Davydov DR
Biochem Pharmacol; 2018 Oct; 156():86-98. PubMed ID: 30114388
[TBL] [Abstract][Full Text] [Related]
9. Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers.
Madani S; Barilla D; Cramer J; Wang Y; Paul C
J Clin Pharmacol; 2002 Nov; 42(11):1211-8. PubMed ID: 12412819
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effects of polyphenols and their colonic metabolites on CYP2D6 enzyme using two different substrates.
Fliszár-Nyúl E; Mohos V; Csepregi R; Mladěnka P; Poór M
Biomed Pharmacother; 2020 Nov; 131():110732. PubMed ID: 32942157
[TBL] [Abstract][Full Text] [Related]
11. The impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy).
Van LM; Heydari A; Yang J; Hargreaves J; Rowland-Yeo K; Lennard MS; Tucker GT; Rostami-Hodjegan A
J Psychopharmacol; 2006 Nov; 20(6):834-41. PubMed ID: 16478752
[TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of potent CYP2D6 inhibitors in lotus leaves.
Ye LH; He XX; Kong LT; Liao YH; Pan RL; Xiao BX; Liu XM; Chang Q
J Ethnopharmacol; 2014 Apr; 153(1):190-6. PubMed ID: 24561383
[TBL] [Abstract][Full Text] [Related]
13. Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57).
Sakuyama K; Sasaki T; Ujiie S; Obata K; Mizugaki M; Ishikawa M; Hiratsuka M
Drug Metab Dispos; 2008 Dec; 36(12):2460-7. PubMed ID: 18784265
[TBL] [Abstract][Full Text] [Related]
14. Mechanism-based inactivation of cytochrome P450 2D6 by chelidonine.
Liu Y; Cui T; Peng Y; Ji M; Zheng J
J Biochem Mol Toxicol; 2019 Feb; 33(2):e22251. PubMed ID: 30368994
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic interaction between nortriptyline and terbinafine.
Van Der Kuy PH; Van Den Heuvel HA; Kempen RW; Vanmolkot LM
Ann Pharmacother; 2002 Nov; 36(11):1712-4. PubMed ID: 12398564
[TBL] [Abstract][Full Text] [Related]
16. Effect of genetic polymorphism on the inhibition of dopamine formation from p-tyramine catalyzed by brain cytochrome P450 2D6.
Niwa T; Shizuku M; Yamano K
Arch Biochem Biophys; 2017 Apr; 620():23-27. PubMed ID: 28347660
[TBL] [Abstract][Full Text] [Related]
17. Functional characterization of wild-type and 24 CYP2D6 allelic variants on gefitinib metabolism in vitro.
Fang P; Zheng X; He J; Ge H; Tang P; Cai J; Hu G
Drug Des Devel Ther; 2017; 11():1283-1290. PubMed ID: 28461741
[TBL] [Abstract][Full Text] [Related]
18. Selective inhibition of cytochrome P450 2D6 by Sarpogrelate and its active metabolite, M-1, in human liver microsomes.
Cho DY; Bae SH; Lee JK; Kim YW; Kim BT; Bae SK
Drug Metab Dispos; 2014 Jan; 42(1):33-9. PubMed ID: 24167220
[TBL] [Abstract][Full Text] [Related]
19. Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms.
Yu A; Kneller BM; Rettie AE; Haining RL
J Pharmacol Exp Ther; 2002 Dec; 303(3):1291-300. PubMed ID: 12438554
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the Mechanism of Prolonged Persistence of Drug Interaction between Terbinafine and Amitriptyline or Nortriptyline.
Mikami A; Hori S; Ohtani H; Sawada Y
Biol Pharm Bull; 2017; 40(7):1010-1020. PubMed ID: 28674244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
